For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Survodutide is a dual glucagon receptor and GLP-1 receptor agonist in active Phase 3 development by Boehringer Ingelheim. Phase 2 data published in the NEJM (MASH, 62% resolution at 4.8 mg) and Lancet Diabetes and Endocrinology (obesity, 14.9% planned-treatment weight loss at 4.8 mg, 18.7% in completers at 46 weeks) established strong efficacy signals. Phase 3 SYNCHRONIZE-1 topline results announced April 28, 2026: 16.6% mean weight loss at 76 weeks vs 3.2% placebo (p less than 0.0001), meeting both co-primary endpoints in 725 participants without T2D, with most weight loss coming from fat tissue and lean mass contributing only a small proportion. MASH Phase 3 LIVERAGE results expected later 2026.
Survodutide is not yet approved for any indication as of May 2026. It is an investigational pharmaceutical drug in Phase 3 clinical development, not a research chemical or supplement. It cannot be obtained outside a formal clinical trial. There is no compounding authorization and no off-label prescribing pathway.
Phase 3 SYNCHRONIZE-1 topline results were announced on April 28, 2026 by Boehringer Ingelheim. Survodutide met both co-primary endpoints: adults with obesity or overweight without T2D lost up to an average of 16.6% of body weight after 76 weeks using the efficacy estimand, versus 3.2% placebo (p less than 0.0001). Up to 85.1% achieved at least 5% body weight reduction versus 38.8% placebo. Full data will be presented at the American Diabetes Association 2026 Scientific Sessions. These are topline results only; full peer-reviewed publication and FDA submission are pending.
A notable finding from SYNCHRONIZE-1: initial analysis suggested most weight loss came from fat tissue, with lean mass contributing only a small proportion. If confirmed in full data, this would distinguish survodutide from semaglutide and tirzepatide, both of which have documented lean mass losses. The clinical significance of lean mass preservation depends on resistance exercise context and long-term follow-up.
The 25% treatment discontinuation rate due to adverse events in the Phase 2 obesity trial (versus 4% placebo) remains the most clinically significant safety signal from the Phase 2 program. Most discontinuations were GI-related and occurred during dose escalation. Phase 3 SYNCHRONIZE trials implement slower escalation to address this. Whether Phase 3 produced a substantially lower discontinuation rate will be confirmed in the full SYNCHRONIZE-1 data presentation.
MASH Phase 3 (LIVERAGE and LIVERAGE-Cirrhosis) and T2D Phase 3 (SYNCHRONIZE-2) results are expected later in 2026. Cardiovascular outcomes data (SYNCHRONIZE-CVOT, n=4,935 target) will not be available for several years.
Survodutide (BI 456906) is a synthetic peptide developed by Boehringer Ingelheim in collaboration with Zealand Pharma, derived structurally from glucagon with a C18 fatty diacid moiety incorporated to enable once-weekly subcutaneous dosing. Boehringer Ingelheim holds sole responsibility for global development and commercialization, with Zealand Pharma retaining co-promotion rights in the Nordic countries.
The compound was engineered with greater potency bias toward the GLP-1 receptor (EC50 approximately 1 nM) than the glucagon receptor (EC50 approximately 8 nM), capturing the glycemic control and appetite suppression of GLP-1R agonism while adding the energy expenditure and direct hepatic effects of glucagon receptor agonism.
GLP-1 receptor activation suppresses appetite, slows gastric emptying, and improves insulin secretion. Glucagon receptor activation stimulates hepatic fat oxidation, increases energy expenditure, and promotes lipolysis in adipose tissue. The glucagon receptor is highly expressed in the liver, providing mechanistic rationale for survodutide's particular efficacy in MASH: a condition driven by hepatic fat accumulation and inflammation.
The drug's development accelerated substantially after Phase 2 results were presented at the ADA 83rd Scientific Sessions in June 2024 and simultaneously published in the Lancet Diabetes and Endocrinology (obesity) and NEJM (MASH). Phase 3 SYNCHRONIZE-1 positive topline results were announced April 28, 2026.
Survodutide activates the GLP-1 receptor and the glucagon receptor through two complementary pathways.
GLP-1 receptor activation reduces energy intake via hypothalamic appetite suppression, slows gastric emptying, stimulates glucose-dependent insulin secretion, and provides cardiovascular protective effects consistent with the approved GLP-1R agonist class.
Glucagon receptor activation adds: stimulation of hepatic fat oxidation and mitochondrial uncoupling (directly reducing steatosis), increased adipose tissue lipolysis, elevated energy expenditure via thermogenesis, and hepatic glycogenolysis. The glucagon receptor is highly expressed in the liver, making glucagon receptor agonism a mechanistic driver of the drug's hepatic efficacy in MASH and a theoretical differentiator from GIP-based dual agonists like tirzepatide.
The GLP-1R bias (EC50 approximately 1 nM vs 8 nM GCGR) leverages GLP-1R-mediated insulin secretion to counterbalance the hyperglycemic potential of glucagon receptor activation, maintaining euglycemia while capturing metabolic and hepatic benefits. The Phase 2 T2D data confirmed this: the theoretical hyperglycemia risk from glucagon receptor agonism has not materialized clinically.
The lean mass preservation signal from SYNCHRONIZE-1, if confirmed in full data, may relate to glucagon receptor effects on lipolysis and fat-preferential fuel utilization. The mechanistic basis for lean mass preservation would require further characterization in the full dataset and follow-up studies.
Phase 3 SYNCHRONIZE-1 (n=725, 76 weeks, topline April 2026): survodutide met both co-primary endpoints. Adults with obesity or overweight without T2D lost up to an average of 16.6% of body weight using the efficacy estimand vs 3.2% placebo (p less than 0.0001). Up to 85.1% of participants achieved at least 5% weight reduction vs 38.8% placebo. Initial analysis suggested most weight loss came from fat tissue, with lean mass contributing only a small proportion: a potential differentiator from semaglutide and tirzepatide. GI events were consistent with the GLP-1 class and generally mild to moderate, with no new safety concerns. Full data including discontinuation rates, dose-specific results, and cardiometabolic secondary endpoints will be presented at ADA 2026 Scientific Sessions.
Phase 2 obesity (Le Roux 2024, n=386, 46 weeks): mean body weight changes by planned treatment analysis: -6.2% (0.6 mg), -12.5% (2.4 mg), -13.2% (3.6 mg), -14.9% (4.8 mg) vs -2.8% placebo. Placebo-corrected difference at 4.8 mg: -12.1% (95% CI: -15.0 to -9.2; p less than 0.0001). By actual treatment (completers): -18.7% vs -2.3% placebo. 83% of completers at 4.8 mg achieved at least 5% loss; 69% at least 10%; 55% at least 15%; up to 40% achieved at least 20%. Weight was still declining at week 46 with no plateau. Cardiometabolic secondary endpoints at 4.8 mg (placebo-corrected): body weight -15.8 kg; waist circumference -12.1 cm; systolic BP -6.2 mmHg; diastolic BP -2.9 mmHg.
Phase 2 safety note: 91% adverse event rate, 75% GI disorders, 25% discontinuation (predominantly during escalation). Serious adverse events: 4% vs 7% placebo. Phase 3 uses slower escalation to mitigate this.
The SYNCHRONIZE-1 Phase 3 positive topline result confirms that the Phase 2 weight loss signal is replicating at scale. The 16.6% weight loss at 76 weeks positions survodutide comparably to semaglutide (approximately 15% in STEP-1) and meaningfully below tirzepatide (20.9% in SURMOUNT-1) in obesity without T2D. However, the lean mass preservation signal is potentially important: if confirmed in full data, it would distinguish survodutide on a dimension where both approved incretin drugs have documented weaknesses. Full Phase 3 data at ADA 2026 will be critical for understanding dose-specific results, discontinuation rates, and cardiometabolic secondary endpoints before FDA submission.
Primary endpoint met (MASH improvement without fibrosis worsening): 47% (2.4 mg), 62% (4.8 mg), 43% (6.0 mg) vs 14% placebo (p less than 0.001 for quadratic dose-response). The lower efficacy at 6.0 mg vs 4.8 mg is consistent with GI intolerability at the higher dose reducing on-treatment exposure.
Secondary endpoints: at least 30% liver fat reduction: 63%, 67%, 57% vs 14% placebo. At least 1-stage fibrosis improvement: 34%, 36%, 34% vs 22% placebo.
FDA granted Breakthrough Therapy designation for non-cirrhotic MASH with F2 to F3 fibrosis in September 2024, reflecting the data quality and the unmet need in this population. EMA accepted survodutide into its PRIME scheme in November 2023. LIVERAGE Phase 3 MASH program is enrolling with results expected later 2026.
The 62% MASH resolution rate at 4.8 mg substantially exceeds placebo and is competitive with resmetirom (FDA-approved March 2024), which showed approximately 38% resolution in the MAESTRO-NASH Phase 3. The fibrosis improvement signal (36% at least 1-stage improvement) is clinically meaningful, though the fibrosis endpoint at 4.8 mg (36%) was not dramatically superior to placebo (22%), which is a modest absolute difference. FDA Breakthrough Therapy designation confirms the agency's view of the data quality. The glucagon receptor's direct hepatic fat oxidation mechanism provides a pharmacological rationale for survodutide's MASH efficacy that is mechanistically distinct from GLP-1-only approaches. LIVERAGE Phase 3 results are the definitive test.
At the highest once-weekly dose (2.7 mg): HbA1c reduction -1.56% (-17.01 mmol/mol) from baseline of approximately 8.1%. At 1.8 mg twice weekly: -1.68% (-18.38 mmol/mol). Semaglutide 1 mg: -1.47% (-16.07 mmol/mol). Body weight: -8.7% (highest survodutide dose) vs -5.3% semaglutide. Adverse event rate: 77.8% survodutide vs 52.0% semaglutide and 52.5% placebo, primarily GI.
The theoretical hyperglycemia risk from glucagon receptor agonism has not materialized: glycemic control was comparable to semaglutide, consistent with the GLP-1R bias counterbalancing glucagon's hyperglycemic effect. The 16-week duration limits interpretation. SYNCHRONIZE-2 Phase 3 (76-week) will provide definitive T2D data.
Comparable glycemic control to semaglutide with greater body weight reduction; more GI adverse events. The glucagon receptor's theoretical hyperglycemia risk has not materialized, which is an important mechanistic confirmation. The 16-week duration is a meaningful limitation for a drug intended for chronic use. SYNCHRONIZE-2 Phase 3 results are pending later 2026.
Phase 2 obesity: adverse event rate 91% survodutide vs 75% placebo. GI disorders: 75% vs 42%. Discontinuation due to adverse events: 25% vs 4%, the majority during the 20-week escalation phase. Nausea 66% vs 23%, diarrhea 49% vs 23%, vomiting 41% vs 11%. Serious adverse events: 4% vs 7%. The lower serious adverse event rate in the survodutide group indicates GI events were prevalent but not life-threatening.
Phase 3 design modification (Wharton 2025): SYNCHRONIZE trials use slower escalation starting at 1 mg, increasing over approximately 32 weeks to maximum maintenance doses (3.6 or 6.0 mg). The Phase 2 discontinuation rate occurred predominantly during a faster 20-week escalation phase.
SYNCHRONIZE-1 topline safety (April 2026): GI events were consistent with the GLP-1 class and generally mild to moderate, occurring more frequently during dose escalation. No new safety concerns were observed. Detailed discontinuation rates from Phase 3 will be available in the full data presentation at ADA 2026.
A 25% adverse event-driven discontinuation rate (vs 4% placebo) in Phase 2 is the most important safety signal in the program. The mechanism is clear (GI effects during rapid escalation) and the mitigation is credible (slower Phase 3 escalation). The SYNCHRONIZE-1 topline characterization of GI events as mild to moderate and consistent with the GLP-1 class is encouraging, but the full discontinuation data from Phase 3 will be the definitive answer to the commercial viability question. For a chronic obesity medication intended for indefinite use, approximately 1 in 4 patients in Phase 2 could not continue treatment: a number the entire obesity drug field is watching Phase 3 to revise.
SYNCHRONIZE-CVOT (enrolling as of May 2026): n=4,935 target; three arms (survodutide 6.0 mg, survodutide 3.6 mg, placebo weekly SC); primary endpoint is time to first 5-point MACE (death, non-fatal stroke, non-fatal MI, ischemia-related coronary revascularization, heart failure event). Stratified by heart failure status and T2D status.
Context: semaglutide's SELECT trial (2023) demonstrated 20% reduction in major CV events in people with obesity without T2D. SYNCHRONIZE-CVOT will determine whether dual GCGR/GLP-1R agonism achieves similar or superior CV outcomes. The glucagon component's known effects on heart rate require formal CV safety assessment. CV outcomes data will not be available for several years after the obesity Phase 3 results.
CV outcomes data will not be available until several years after potential survodutide approval. If survodutide is approved in 2027 or 2028, prescribers will face an uncertain CV safety profile until CVOT completion: standard for newly approved obesity drugs but clinically important context. The glucagon component adds a theoretical heart rate question that the GLP-1-only class does not carry. Prescribers will need to weigh SYNCHRONIZE-CVOT absence against the established CV benefits of approved GLP-1 receptor agonists when making drug selection decisions.
Survodutide is not available outside formal clinical trials as of May 2026. There is no prescription pathway, no compounding authorization, and no off-label access. Phase 3 SYNCHRONIZE-1 positive topline results announced April 28, 2026. Full data presentation at ADA 2026 Scientific Sessions. LIVERAGE MASH Phase 3, SYNCHRONIZE-2 T2D Phase 3, and SYNCHRONIZE-CVOT cardiovascular outcomes trial results pending. FDA approval timeline dependent on full data submission following 2026 Phase 3 readouts.
Survodutide vs semaglutide and tirzepatide: Phase 3 SYNCHRONIZE-1 (16.6% at 76 weeks) positions survodutide comparably to semaglutide STEP-1 (14.9% at 68 weeks) and below tirzepatide SURMOUNT-1 (20.9% at 72 weeks). The lean mass preservation signal from SYNCHRONIZE-1 is the key potential differentiator: semaglutide and tirzepatide both document lean mass losses. MASH indication: survodutide's glucagon receptor mechanism directly drives hepatic fat oxidation; tirzepatide's MASH Phase 2 data (Loomba et al., NEJM 2024) showed approximately 49 to 62% MASH resolution at 10 mg, making these competitive. Approved MASH drug resmetirom showed approximately 38% resolution in Phase 3 MAESTRO-NASH.
Survodutide vs retatrutide (mechanistic comparison): retatrutide adds GIP agonism to the GLP-1 plus glucagon dual agonism of survodutide, achieving 28.7% weight loss in TRIUMPH Phase 3. Both carry the glucagon receptor component that provides direct hepatic fat oxidation. Retatrutide's triple agonism achieves greater weight loss but has not yet published MASH-specific Phase 3 data. These may ultimately compete directly in both obesity and MASH indications.
Phase 2 obesity trial (Le Roux 2024, n=386, 46 weeks): adverse events in 91% of survodutide recipients vs 75% placebo. GI disorders: 75% vs 42%. Discontinuation due to adverse events: 25% vs 4%, the majority during the 20-week escalation phase. Nausea (66% vs 23%), diarrhea (49% vs 23%), vomiting (41% vs 11%). Serious adverse events: 4% survodutide vs 7% placebo. The lower serious adverse event rate in the survodutide group indicates GI events were prevalent but not life-threatening.
Blood pressure favorable: at 4.8 mg, placebo-corrected reductions of -6.2 mmHg systolic and -2.9 mmHg diastolic at 46 weeks.
No pancreatitis signal identified. Heart rate increases consistent with the mechanism were observed.
Phase 3 SYNCHRONIZE trials use a significantly slower escalation schedule (starting at 1 mg, escalating over approximately 32 weeks to maximum 3.6 or 6.0 mg) specifically designed to reduce GI-driven discontinuations. The SYNCHRONIZE-1 topline announcement noted GI events were consistent with the GLP-1 class and were generally mild to moderate, occurring more frequently during dose escalation, with no new safety concerns observed. Detailed safety and discontinuation data from Phase 3 will be presented at ADA 2026.
Survodutide is the most clinically advanced investigational compound in The Peptide Signal database as of May 2026. Phase 3 SYNCHRONIZE-1 positive topline results announced April 28, 2026 confirmed that the Phase 2 weight loss signal is replicating at scale: 16.6% mean weight loss at 76 weeks in 725 participants, meeting both co-primary endpoints. The lean mass preservation signal, if confirmed in full data, would represent a clinically meaningful differentiator from semaglutide and tirzepatide.
The weight loss hierarchy is becoming clearer: retatrutide (28.7%, Phase 3, awaiting approval) is above tirzepatide (20.9%, approved) which is above survodutide (16.6%, Phase 3 positive topline) which is above semaglutide (14.9%, approved) in obesity without T2D. Survodutide's 16.6% positions it comparably to semaglutide on pure weight loss magnitude, but the lean mass preservation and the MASH indication provide potential clinical differentiation.
The MASH indication is where survodutide has the clearest clinical differentiation from all currently approved drugs except resmetirom. The Phase 2 NEJM data showing 62% MASH resolution is compelling and the glucagon receptor mechanism directly addresses the hepatic fat accumulation pathology. LIVERAGE Phase 3 results are the critical next readout, expected later 2026.
Two important limitations remain: the 25% GI-driven discontinuation rate from Phase 2 (pending full Phase 3 characterization from ADA 2026) and the absence of cardiovascular outcomes data, which will not be available until years after potential approval. FDA submission and approval timeline remain dependent on full data package assembly following the 2026 Phase 3 readouts.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use